Loading…

Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes

Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity. Natalizumab and alemtuzumab are the only two currently approved mAbs for the treatment of MS, having demonstrated...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in neurological disorders 2015-11, Vol.8 (6), p.274-293
Main Author: Lycke, Jan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c571t-8dda706d2eae5eb054ba27c857e37eee1363905712c468f59e2368e365495c833
cites cdi_FETCH-LOGICAL-c571t-8dda706d2eae5eb054ba27c857e37eee1363905712c468f59e2368e365495c833
container_end_page 293
container_issue 6
container_start_page 274
container_title Therapeutic advances in neurological disorders
container_volume 8
creator Lycke, Jan
description Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity. Natalizumab and alemtuzumab are the only two currently approved mAbs for the treatment of MS, having demonstrated significant reduction in clinical and magnetic resonance imaging disease activity and disability in clinical studies. Ocrelizumab and daclizumab are in the late stages of phase III trials, and several other mAbs are in the early stages of clinical evaluation. mAbs have distinct structural characteristics (e.g. chimeric, humanized, fully human) and unique targets (e.g. blocking interactions, induction of signal transduction by receptor binding, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity) conferring different mechanisms of action in MS. Because of these differences, mAbs for MS do not constitute a single treatment class; each must be considered individually when selecting appropriate therapy. Furthermore, in reviewing the data from clinical studies of mAbs, attention should be drawn to use of different comparators (e.g. placebo or interferon β-1a) and study designs. Each mAb treatment has a unique administration schedule. In the decision to select the appropriate treatment for each individual MS patient, careful review of the benefits relative to risks of mAbs is balanced against the risk of development of MS-associated disability.
doi_str_mv 10.1177/1756285615605429
format article
fullrecord <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_90213f189d21467ca3e099eed01571bc</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1756285615605429</sage_id><doaj_id>oai_doaj_org_article_90213f189d21467ca3e099eed01571bc</doaj_id><sourcerecordid>1765979077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c571t-8dda706d2eae5eb054ba27c857e37eee1363905712c468f59e2368e365495c833</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEoqVw54Ry5BKwnfiLAxKq-KhUxAXOlmNPsl45cbCdov4G_jReUlZdJCROHo_f9xmPPVX1HKNXGHP-GnPKiKAMU4ZoR-SD6vyQaohg3cNjTNlZ9SSlPUKM8A49rs4IYwgJTs6rn5_DHIwPs_a1nrPrg72t8w6iXhykegjxsKtzBJ0nmHMdhjqC10ty89hEmFzOJaqn1We3eKiT8RBDculNbd0wQCwmpzcNmJ2eXZpSKWVr493sTKkb1mzCBOlp9WjQPsGzu_Wi-vbh_dfLT831l49Xl--uG0M5zo2wVnPELAENFPrSeK8JN4JyaDkA4Ja1EhUpMR0TA5VAWiagZbST1Ii2vaiuNq4Neq-W6CYdb1XQTv1OhDgqHbMrjSiJCG4HLKQluGPc6BaQlAAW4VKgN4XVbKz0A5a1P6GN66JKalxVAkUIK46if7vpi3gCa8rrRO1PbKcns9upMdyojnWtYKIAXt4BYvi-QspqcsmA93qGsCaFOaOSS8T5f0g7yVCHyYGKNqkpf5ciDMcbYaQOo6b-HrVieXG_k6Phz2zdexo9gtqHNZYhS_8G_gJUNd-D</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1749604128</pqid></control><display><type>article</type><title>Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes</title><source>Sage Journals GOLD Open Access 2024</source><creator>Lycke, Jan</creator><creatorcontrib>Lycke, Jan</creatorcontrib><description>Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity. Natalizumab and alemtuzumab are the only two currently approved mAbs for the treatment of MS, having demonstrated significant reduction in clinical and magnetic resonance imaging disease activity and disability in clinical studies. Ocrelizumab and daclizumab are in the late stages of phase III trials, and several other mAbs are in the early stages of clinical evaluation. mAbs have distinct structural characteristics (e.g. chimeric, humanized, fully human) and unique targets (e.g. blocking interactions, induction of signal transduction by receptor binding, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity) conferring different mechanisms of action in MS. Because of these differences, mAbs for MS do not constitute a single treatment class; each must be considered individually when selecting appropriate therapy. Furthermore, in reviewing the data from clinical studies of mAbs, attention should be drawn to use of different comparators (e.g. placebo or interferon β-1a) and study designs. Each mAb treatment has a unique administration schedule. In the decision to select the appropriate treatment for each individual MS patient, careful review of the benefits relative to risks of mAbs is balanced against the risk of development of MS-associated disability.</description><identifier>ISSN: 1756-2856</identifier><identifier>ISSN: 1756-2864</identifier><identifier>EISSN: 1756-2864</identifier><identifier>DOI: 10.1177/1756285615605429</identifier><identifier>PMID: 26600872</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>alpha-4 integrin expression ; antibodies ; autoimmunity ; central-nervous-system ; controlled phase-3 trial ; double-blind ; encephalomyelitis ; experimental autoimmune ; high-yield ; monoclonal ; multiple sclerosis ; natalizumab treatment interruption ; Neurologi ; Neurology ; Neurosciences ; Neurosciences &amp; Neurology ; Neurovetenskaper ; placebo-controlled trial ; process ; progressive multifocal leukoencephalopathy ; Reviews ; therapeutic lymphocyte depletion ; therapy</subject><ispartof>Therapeutic advances in neurological disorders, 2015-11, Vol.8 (6), p.274-293</ispartof><rights>The Author(s), 2015</rights><rights>The Author(s), 2015 2015 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c571t-8dda706d2eae5eb054ba27c857e37eee1363905712c468f59e2368e365495c833</citedby><cites>FETCH-LOGICAL-c571t-8dda706d2eae5eb054ba27c857e37eee1363905712c468f59e2368e365495c833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,313,314,723,776,780,788,881,21942,27827,27896,27898,27899,44918,45306,53763,53765</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1756285615605429?utm_source=summon&amp;utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26600872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/226571$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Lycke, Jan</creatorcontrib><title>Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes</title><title>Therapeutic advances in neurological disorders</title><addtitle>Ther Adv Neurol Disord</addtitle><description>Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity. Natalizumab and alemtuzumab are the only two currently approved mAbs for the treatment of MS, having demonstrated significant reduction in clinical and magnetic resonance imaging disease activity and disability in clinical studies. Ocrelizumab and daclizumab are in the late stages of phase III trials, and several other mAbs are in the early stages of clinical evaluation. mAbs have distinct structural characteristics (e.g. chimeric, humanized, fully human) and unique targets (e.g. blocking interactions, induction of signal transduction by receptor binding, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity) conferring different mechanisms of action in MS. Because of these differences, mAbs for MS do not constitute a single treatment class; each must be considered individually when selecting appropriate therapy. Furthermore, in reviewing the data from clinical studies of mAbs, attention should be drawn to use of different comparators (e.g. placebo or interferon β-1a) and study designs. Each mAb treatment has a unique administration schedule. In the decision to select the appropriate treatment for each individual MS patient, careful review of the benefits relative to risks of mAbs is balanced against the risk of development of MS-associated disability.</description><subject>alpha-4 integrin expression</subject><subject>antibodies</subject><subject>autoimmunity</subject><subject>central-nervous-system</subject><subject>controlled phase-3 trial</subject><subject>double-blind</subject><subject>encephalomyelitis</subject><subject>experimental autoimmune</subject><subject>high-yield</subject><subject>monoclonal</subject><subject>multiple sclerosis</subject><subject>natalizumab treatment interruption</subject><subject>Neurologi</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Neurosciences &amp; Neurology</subject><subject>Neurovetenskaper</subject><subject>placebo-controlled trial</subject><subject>process</subject><subject>progressive multifocal leukoencephalopathy</subject><subject>Reviews</subject><subject>therapeutic lymphocyte depletion</subject><subject>therapy</subject><issn>1756-2856</issn><issn>1756-2864</issn><issn>1756-2864</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqNkk1v1DAQhiMEoqVw54Ry5BKwnfiLAxKq-KhUxAXOlmNPsl45cbCdov4G_jReUlZdJCROHo_f9xmPPVX1HKNXGHP-GnPKiKAMU4ZoR-SD6vyQaohg3cNjTNlZ9SSlPUKM8A49rs4IYwgJTs6rn5_DHIwPs_a1nrPrg72t8w6iXhykegjxsKtzBJ0nmHMdhjqC10ty89hEmFzOJaqn1We3eKiT8RBDculNbd0wQCwmpzcNmJ2eXZpSKWVr493sTKkb1mzCBOlp9WjQPsGzu_Wi-vbh_dfLT831l49Xl--uG0M5zo2wVnPELAENFPrSeK8JN4JyaDkA4Ja1EhUpMR0TA5VAWiagZbST1Ii2vaiuNq4Neq-W6CYdb1XQTv1OhDgqHbMrjSiJCG4HLKQluGPc6BaQlAAW4VKgN4XVbKz0A5a1P6GN66JKalxVAkUIK46if7vpi3gCa8rrRO1PbKcns9upMdyojnWtYKIAXt4BYvi-QspqcsmA93qGsCaFOaOSS8T5f0g7yVCHyYGKNqkpf5ciDMcbYaQOo6b-HrVieXG_k6Phz2zdexo9gtqHNZYhS_8G_gJUNd-D</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Lycke, Jan</creator><general>SAGE Publications</general><general>SAGE Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>F1U</scope><scope>DOA</scope></search><sort><creationdate>20151101</creationdate><title>Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes</title><author>Lycke, Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c571t-8dda706d2eae5eb054ba27c857e37eee1363905712c468f59e2368e365495c833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>alpha-4 integrin expression</topic><topic>antibodies</topic><topic>autoimmunity</topic><topic>central-nervous-system</topic><topic>controlled phase-3 trial</topic><topic>double-blind</topic><topic>encephalomyelitis</topic><topic>experimental autoimmune</topic><topic>high-yield</topic><topic>monoclonal</topic><topic>multiple sclerosis</topic><topic>natalizumab treatment interruption</topic><topic>Neurologi</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Neurosciences &amp; Neurology</topic><topic>Neurovetenskaper</topic><topic>placebo-controlled trial</topic><topic>process</topic><topic>progressive multifocal leukoencephalopathy</topic><topic>Reviews</topic><topic>therapeutic lymphocyte depletion</topic><topic>therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lycke, Jan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Göteborgs universitet</collection><collection>Directory of Open Access Journals</collection><jtitle>Therapeutic advances in neurological disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Lycke, Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes</atitle><jtitle>Therapeutic advances in neurological disorders</jtitle><addtitle>Ther Adv Neurol Disord</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>8</volume><issue>6</issue><spage>274</spage><epage>293</epage><pages>274-293</pages><issn>1756-2856</issn><issn>1756-2864</issn><eissn>1756-2864</eissn><abstract>Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity. Natalizumab and alemtuzumab are the only two currently approved mAbs for the treatment of MS, having demonstrated significant reduction in clinical and magnetic resonance imaging disease activity and disability in clinical studies. Ocrelizumab and daclizumab are in the late stages of phase III trials, and several other mAbs are in the early stages of clinical evaluation. mAbs have distinct structural characteristics (e.g. chimeric, humanized, fully human) and unique targets (e.g. blocking interactions, induction of signal transduction by receptor binding, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity) conferring different mechanisms of action in MS. Because of these differences, mAbs for MS do not constitute a single treatment class; each must be considered individually when selecting appropriate therapy. Furthermore, in reviewing the data from clinical studies of mAbs, attention should be drawn to use of different comparators (e.g. placebo or interferon β-1a) and study designs. Each mAb treatment has a unique administration schedule. In the decision to select the appropriate treatment for each individual MS patient, careful review of the benefits relative to risks of mAbs is balanced against the risk of development of MS-associated disability.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26600872</pmid><doi>10.1177/1756285615605429</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1756-2856
ispartof Therapeutic advances in neurological disorders, 2015-11, Vol.8 (6), p.274-293
issn 1756-2856
1756-2864
1756-2864
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_90213f189d21467ca3e099eed01571bc
source Sage Journals GOLD Open Access 2024
subjects alpha-4 integrin expression
antibodies
autoimmunity
central-nervous-system
controlled phase-3 trial
double-blind
encephalomyelitis
experimental autoimmune
high-yield
monoclonal
multiple sclerosis
natalizumab treatment interruption
Neurologi
Neurology
Neurosciences
Neurosciences & Neurology
Neurovetenskaper
placebo-controlled trial
process
progressive multifocal leukoencephalopathy
Reviews
therapeutic lymphocyte depletion
therapy
title Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-26T10%3A06%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monoclonal%20antibody%20therapies%20for%20the%20treatment%20of%20relapsing-remitting%20multiple%20sclerosis:%20differentiating%20mechanisms%20and%20clinical%20outcomes&rft.jtitle=Therapeutic%20advances%20in%20neurological%20disorders&rft.au=Lycke,%20Jan&rft.date=2015-11-01&rft.volume=8&rft.issue=6&rft.spage=274&rft.epage=293&rft.pages=274-293&rft.issn=1756-2856&rft.eissn=1756-2864&rft_id=info:doi/10.1177/1756285615605429&rft_dat=%3Cproquest_AFRWT%3E1765979077%3C/proquest_AFRWT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c571t-8dda706d2eae5eb054ba27c857e37eee1363905712c468f59e2368e365495c833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1749604128&rft_id=info:pmid/26600872&rft_sage_id=10.1177_1756285615605429&rfr_iscdi=true